MedPath

Octafluoropropane

Generic Name
Octafluoropropane
Brand Names
Definity, Luminity, Optison
Drug Type
Small Molecule
Chemical Formula
C3F8
CAS Number
76-19-7
Unique Ingredient Identifier
CK0N3WH0SR

Overview

Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.

Background

Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.

Indication

Used as an ultrasound contrast imaging in cardiology and radiology.

Associated Conditions

No associated conditions information available.

FDA Approved Products

Optison Perflutren Protein-Type A Microspheres
Manufacturer:GE Healthcare Inc.
Route:INTRAVENOUS
Strength:0.22 mg in 1 mL
Approved: 2022/12/30
NDC:0407-2707
Definity
Manufacturer:Lantheus Medical Imaging, Inc.
Route:INTRAVENOUS
Strength:6.52 mg in 1 mL
Approved: 2024/03/13
NDC:11994-011
DEFINITY RT
Manufacturer:Lantheus Medical Imaging, Inc.
Route:INTRAVENOUS
Strength:6.52 mg in 1 mL
Approved: 2024/03/13
NDC:11994-017

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath